Table 4. Safety indicators in the YH1 and placebo groups.
| Safety Indicators at Week 12 | YH1 Group (n = 21) |
Placebo Group (n = 20) |
p value |
|---|---|---|---|
| median (min, max) | median (min, max) | ||
| Systolic BP (mmHg) | 132.0 (111.0, 150.0) | 126.0 (97.0, 167.0) | .22 |
| Diastolic BP (mmHg) | 75.0 (64.0, 89.0) | 73.5 (52.0, 100.0) | .31 |
| Heart rate (beats/min) | 82.0 (69.0, 108.0) | 80.5 (61.0, 111.0) | .61 |
| ALT (U/L) | 27.0 (7.0, 76.0) | 24.5 (14.0, 49.0) | .87 |
| Creatinine (mg/dL) | 0.69 (0.34, 1.00) | 0.62 (0.36, 1.13) | .81 |
To assess the relative change in numerical data between groups, the Mann–Whitney U test was applied to determine significance. No significant changes in blood pressure, heart rate, plasma ALT or creatinine were observed between the YH1 and placebo groups during the 12 weeks of treatment. BP, blood pressure; ALT, alanine aminotransferase.